imuno® compared to GcMAF

The figure above compares the descending trend of two cancer markers following immunotherapy with GcMAF Forte or imuno.
GcMAF Forte was used together with thymus peptide extracts for about 15 months (March 2015 – May 2016) in a patient with metastatic colorectal carcinoma.
The examined cancer marker was CEA (serum carcinoembryonic antigen) a recognized cancer marker that, however, is not specific for colorectal carcinoma.
The final value for CEA was about 36% of the initial value with a decrease of about 65%.
imuno was used for about 7 months (October 2018-May 2019) in a patient with multiple myeloma.
The examined cancer marker was the ratio of serum free Kappa and Lambda light chains, a marker highly specific for the disease.
The final value was about 1.68% of the initial value with a decrease of about 98%.
In short, GcMAF Forte decreased a cancer marker by 65% in 15 months; imuno by 98% in 7 months.
The original values for each cancer marker are reported in the figure; the graphs are drawn considering the initial value for each cancer marker, i.e. the value before treatment, as 100%.
All the data used to draw this figure are in the open access public domain.

The figure above compares the descending trend of two cancer markers following immunotherapy with GcMAF Forte or imuno.
This figure refers to the same patients described in the previous figure.
In this figure, the comparison between two month treatment with GcMAF Forte and three month treatment with imuno is drawn in the left panel.
The comparison between eight month treatment with GcMAF Forte and seven month treatment with imuno is drawn in the right panel.
In both cases, the greater efficiency of imuno in lowering a specific cancer marker is evident.
The original values for each cancer marker are reported in the figure; the histograms are drawn considering the initial value for each cancer marker, i.e. the value before treatment, as 100%.
All the data used to draw this figure are in the open access public domain.

The figure above compares the descending trend of two cancer markers following immunotherapy with second generation GcMAF or imuno.
Second generation GcMAF was used together with sonodynamic therapy and tumor treating fields patient for about 4 months (November 2014 – March 2016) in a patient with non-small cell lung cancer.
The examined cancer marker was neuron specific enolase (NSE), a recognized cancer marker that, however, is considered to show low sensitivity in non-small cell lung cancer (Lung Cancer. Vol 31, Issues 2–3, March 2001, pp 221-231).
The final value for NSEwas about 77% of the initial value with a decrease of about 23%.
imuno was used for about 3 months (October 2018-January 2019) in a patient with multiple myeloma.
The examined cancer marker was the ratio of serum free Kappa and Lambda light chains, a marker highly specific for the disease.
The final value was about 5.93% of the initial value with a decrease of about 94%.
The original values for each cancer marker are reported in the figure; the histograms are drawn considering the initial value for each cancer marker, i.e. the value before treatment, as 100%.
All the data used to draw this figure are in the open access public domain.

imuno® versus GcMAF